Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?
Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous compl...
Gespeichert in:
Veröffentlicht in: | Pediatric dermatology 2023-07, Vol.40 (4), p.678-680 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 680 |
---|---|
container_issue | 4 |
container_start_page | 678 |
container_title | Pediatric dermatology |
container_volume | 40 |
creator | Barry, Kelly K. Neale, Holly D. Hawryluk, Elena B. |
description | Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy. |
doi_str_mv | 10.1111/pde.15226 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2836334686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2836334686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</originalsourceid><addsrcrecordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxbS6TTOpGpLYqFnRR1-F0JqEpc6lJB-nOR_AZfRIzTnXn2Rz4-fgO50fonOAhCTPa5HpIOKXiAPXD5jFJUnyI-jhlIpY4ET104v0aYyyFIMeoxwRPWSJkHz0tmrJ2UaUzV3vrIwPZtnZfH59QbFYQ2WpllzYkPoIqjyCrdGSaorQVVP46mjmrQxwEptY3p-jIQOH12X4P0Otsupg8xPPn-8fJ7TzOGMUiBmBcYpAEtKGZ1jyVnC0xjDHhcpxDSlmWm3FCeQJCSMEM54xgRrUOoRFsgC4778bVb432W7WuG1eFk4pKJlj7WUtddVT7mXfaqI2zJbidIli1talQm_qpLbAXe2OzLHX-R_72FIBRB7zbQu_-N6mXu2mn_AZ-cnYF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2836334686</pqid></control><display><type>article</type><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><source>Wiley Online Library All Journals</source><creator>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</creator><creatorcontrib>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</creatorcontrib><description>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15226</identifier><identifier>PMID: 36573468</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acne ; acne fulminans ; adalimumab ; adverse reaction ; Crohn disease ; Crohn's disease ; Eruptions ; Folliculitis ; Hemorrhage ; Inflammation ; Inflammatory bowel diseases ; Monoclonal antibodies ; paradoxical ; Pediatrics ; Pyoderma ; Pyoderma gangrenosum ; Side effects ; Skin eruptions ; Sweet's syndrome ; TNF‐alpha ; tofacitinib ; Tumor necrosis factor</subject><ispartof>Pediatric dermatology, 2023-07, Vol.40 (4), p.678-680</ispartof><rights>2022 Wiley Periodicals LLC.</rights><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</citedby><cites>FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</cites><orcidid>0000-0003-0382-4470 ; 0000-0003-0361-3657 ; 0000-0002-0862-3339</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpde.15226$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpde.15226$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36573468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barry, Kelly K.</creatorcontrib><creatorcontrib>Neale, Holly D.</creatorcontrib><creatorcontrib>Hawryluk, Elena B.</creatorcontrib><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><title>Pediatric dermatology</title><addtitle>Pediatr Dermatol</addtitle><description>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</description><subject>Acne</subject><subject>acne fulminans</subject><subject>adalimumab</subject><subject>adverse reaction</subject><subject>Crohn disease</subject><subject>Crohn's disease</subject><subject>Eruptions</subject><subject>Folliculitis</subject><subject>Hemorrhage</subject><subject>Inflammation</subject><subject>Inflammatory bowel diseases</subject><subject>Monoclonal antibodies</subject><subject>paradoxical</subject><subject>Pediatrics</subject><subject>Pyoderma</subject><subject>Pyoderma gangrenosum</subject><subject>Side effects</subject><subject>Skin eruptions</subject><subject>Sweet's syndrome</subject><subject>TNF‐alpha</subject><subject>tofacitinib</subject><subject>Tumor necrosis factor</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKAzEUhoMotlYXvoAMuHIxbS6TTOpGpLYqFnRR1-F0JqEpc6lJB-nOR_AZfRIzTnXn2Rz4-fgO50fonOAhCTPa5HpIOKXiAPXD5jFJUnyI-jhlIpY4ET104v0aYyyFIMeoxwRPWSJkHz0tmrJ2UaUzV3vrIwPZtnZfH59QbFYQ2WpllzYkPoIqjyCrdGSaorQVVP46mjmrQxwEptY3p-jIQOH12X4P0Otsupg8xPPn-8fJ7TzOGMUiBmBcYpAEtKGZ1jyVnC0xjDHhcpxDSlmWm3FCeQJCSMEM54xgRrUOoRFsgC4778bVb432W7WuG1eFk4pKJlj7WUtddVT7mXfaqI2zJbidIli1talQm_qpLbAXe2OzLHX-R_72FIBRB7zbQu_-N6mXu2mn_AZ-cnYF</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Barry, Kelly K.</creator><creator>Neale, Holly D.</creator><creator>Hawryluk, Elena B.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0003-0382-4470</orcidid><orcidid>https://orcid.org/0000-0003-0361-3657</orcidid><orcidid>https://orcid.org/0000-0002-0862-3339</orcidid></search><sort><creationdate>202307</creationdate><title>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</title><author>Barry, Kelly K. ; Neale, Holly D. ; Hawryluk, Elena B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3206-aa3580a81aef2cee57853b0a901589da723cdf94254a66863f5531032ee942f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acne</topic><topic>acne fulminans</topic><topic>adalimumab</topic><topic>adverse reaction</topic><topic>Crohn disease</topic><topic>Crohn's disease</topic><topic>Eruptions</topic><topic>Folliculitis</topic><topic>Hemorrhage</topic><topic>Inflammation</topic><topic>Inflammatory bowel diseases</topic><topic>Monoclonal antibodies</topic><topic>paradoxical</topic><topic>Pediatrics</topic><topic>Pyoderma</topic><topic>Pyoderma gangrenosum</topic><topic>Side effects</topic><topic>Skin eruptions</topic><topic>Sweet's syndrome</topic><topic>TNF‐alpha</topic><topic>tofacitinib</topic><topic>Tumor necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barry, Kelly K.</creatorcontrib><creatorcontrib>Neale, Holly D.</creatorcontrib><creatorcontrib>Hawryluk, Elena B.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barry, Kelly K.</au><au>Neale, Holly D.</au><au>Hawryluk, Elena B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe?</atitle><jtitle>Pediatric dermatology</jtitle><addtitle>Pediatr Dermatol</addtitle><date>2023-07</date><risdate>2023</risdate><volume>40</volume><issue>4</issue><spage>678</spage><epage>680</epage><pages>678-680</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)‐alpha inhibitors have been reported, and rare cutaneous complications include pyoderma gangrenosum, Sweet syndrome‐like hypersensitivity eruptions, and pustular folliculitis. We report an unusual case of AF in a patient with Crohn disease that worsened with doses of adalimumab, which is considered a second‐line treatment for AF. This case highlights that acneiform eruptions may be an underreported paradoxical adverse reaction to anti‐TNF alpha therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36573468</pmid><doi>10.1111/pde.15226</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-0382-4470</orcidid><orcidid>https://orcid.org/0000-0003-0361-3657</orcidid><orcidid>https://orcid.org/0000-0002-0862-3339</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0736-8046 |
ispartof | Pediatric dermatology, 2023-07, Vol.40 (4), p.678-680 |
issn | 0736-8046 1525-1470 |
language | eng |
recordid | cdi_proquest_journals_2836334686 |
source | Wiley Online Library All Journals |
subjects | Acne acne fulminans adalimumab adverse reaction Crohn disease Crohn's disease Eruptions Folliculitis Hemorrhage Inflammation Inflammatory bowel diseases Monoclonal antibodies paradoxical Pediatrics Pyoderma Pyoderma gangrenosum Side effects Skin eruptions Sweet's syndrome TNF‐alpha tofacitinib Tumor necrosis factor |
title | Tumor necrosis factor‐alpha inhibitors and acne fulminans: Friend or foe? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A31%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20necrosis%20factor%E2%80%90alpha%20inhibitors%20and%20acne%20fulminans:%20Friend%20or%20foe?&rft.jtitle=Pediatric%20dermatology&rft.au=Barry,%20Kelly%20K.&rft.date=2023-07&rft.volume=40&rft.issue=4&rft.spage=678&rft.epage=680&rft.pages=678-680&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15226&rft_dat=%3Cproquest_cross%3E2836334686%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2836334686&rft_id=info:pmid/36573468&rfr_iscdi=true |